SCHEMBL3382221

SCHEMBL3382221

NCCCN(CCc1ccccc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.55
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA4 P22748 2/20 0.53
MC5R P33032 3/20 0.53
MC3R P41968 3/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MC4R P32245 2/20 0.50
ALOX5 P09917 1/20 0.50
HTR2A P28223 1/20 0.48
HDAC3 O15379 1/20 0.47
MAPK1 P28482 1/20 0.47
ADRA1A P35348 1/20 0.47
HDAC4 P56524 1/20 0.47
SLC6A3 Q01959 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3383363 0.95 MAOA (0.57) MAOAMC5RMC3RMC4RALOX5
SCHEMBL5933377 0.87 TDP1 (0.66) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL2584582 0.86 LIMK2 (0.56) MC5RMC3RMEN1KMT2ATDP1
SCHEMBL23120228 0.84 TDP1 (0.54) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL26985835 0.83 TDP1 (0.53) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL15796347 0.81 MEN1 (0.51) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL4731326 0.80 TDP1 (0.58) CA12CA1CA2MEN1NPC1
SCHEMBL390751 0.80 NPC1 (0.54) MC5RMC3RMEN1NPC1RAB9A
SCHEMBL7228409 0.80 MEN1 (0.61) CA12CA1CA2CA4MEN1
SCHEMBL30940776 0.79 MC5R (0.46) MAOACA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP MAOA 809/4885CA12 4160/4885CA1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.